ReviewEULAR rheumatology open2026
From 'Me too' to 'Me better' and 'Me cooler': the recent rheumatology advances in China.
Review in EULAR rheumatology open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past 2 years (post-COVID) have witnessed a speeding progression of rheumatology in China. This viewpoint focused on high-impact clinical investigations conducted by researchers from mainland China and highlighted China's contributions that have changed or probably will change clinical practice. It is noteworthy that China is in a process of transitioning from validation studies ('Me too' type) dominance to the enhanced therapeutic strategies and repurposing innovations ('Me better' and 'Me cooler' type), positioning itself as a key player in shaping the future of rheumatology.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.